Activity of uridine kinase in different lines of AKR leukemic mice and its relation to chemotherapy with 5-azacytidine.
The sensitivity of different wild-type and 5-azacytidine-resistant lines of AKR leukemic mice to 5-azacytidine varies in relation to the activity of uridine kinase isolated from corresponding leukemic livers. The enhancement of liver uridine kinase activity observed in leukemic mice following the administration of a single dose of 5-azacytidine is accounted for by the presence of hepatocytes in infiltrated leukemic livers. The optimal schedule for the treatment of AKR leukemic mice with 5-azacytidine requires equally divided doses administered daily and not an initial high dose followed by low doses.
D000818:Animals; D001374:Azacitidine / Q000494:pharmacology* / Q000627:therapeutic use; D002460:Cell Line; D002850:Chromatography, Gel; D003864:Depression, Chemical; D004351:Drug Resistance; D005260:Female; D007942:Leukemia, Experimental / Q000188:drug therapy / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D008806:Mice, Inbred AKR; D012157:Mononuclear Phagocyte System; D010770:Phosphotransferases / Q000378:metabolism*; D013268:Stimulation, Chemical; D013950:Thymus Gland / Q000201:enzymology; D013997:Time Factors; D014541:Uridine Kinase / Q000378:metabolism*
D010770:Phosphotransferases; D014541:Uridine Kinase; D001374:Azacitidine